27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
NeoStem Inc (NASDAQ: NBS) recently received a grant of $17.7 million to fund the company’s effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
NeoStem CEO Dr. David Mazzo was on Fox Business News recently to talk about the company’s new cancer drug.
NBS20
“Our product is called NBS20, it’s too early for us to have a name, but it’s in late stage clinical development,” Mazzo said. “It works by actually identifying within a cancer those cancer stem cells that proliferate and teaching the immune system to actually kill those selectively. So, it’s a way to prolong survival in a way that no other treatment does.”
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
A Simple Procedure
On how the therapy would be delivered, Mazzo said, “It’s actually quite simple. This is what many people call a cancer vaccine. So, it’s administered as a subcutaneous injection. It’s a very simple procedure to administer the drug, a little injection under the skin, once a week for three weeks and then once a month for 5 months and that’s it.”
The Grant
Mazzo was asked about the kind of results the company got for NBS20 that led it to being awarded the $17.7 million grant. He replied, “We actually generated really phenomenal results and two phase-II trials and the most recent of those two was a controlled randomized study where the patients received our treatment had a 72 percent survival rate at 2 years in comparison to a control group which only had a 31 percent and even in that study, that control group was an active control.”
“So, the historical norm for those patients would have been a 25 percent survival rate. So, really a remarkable prolongation of life,” Mazzo said.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.